Experts press for early introduction of Injectable Polio Vaccine (IPV) in India Oct, 2014: Injectable vaccine is much more effective than oral vaccine and eliminates the risk of vaccine-polio. There is also a looming threat of virus importation from Pakistan. These were the inferences drawn during deliberations on the sidelines of Ranbaxy Science Foundation’s 32nd Round Table Conference on “Lessons from the Success of Polio Elimination”.
Trivitron Healthcare signs three MOUs with Pranab Mukherjee to ’Make in India’ Finland, October 2014: Labsystems Diagnostics OY, a Trivitron Healthcare Enterprise has signed a MOU today at Helsinki in the presence of Hon. President of India, Mr. Pranab Mukherjee along with The University of Turku, and Indian Translational Health Science Technology Institute (THSTI). This Indo-Finland initiative will be first of its kind in developing an affordable medical point of care diagnostics device for use in India and other developing countries. This diagnostic platform can be used for testing cardiac troponin-I for acute coronary syndrome and the same can be used for high sensitive detection of several other parameters like Infectious diseases, Cancer Markers, New Born Screening panel etc. The research was funded by Indian Department of Biotechnology under the Ministry of Science and Technology, Tekes (the Finnish Funding Agency for Innovation) & the Academy of Finland.
US FDA approves Gilead's Harvoni to treat chronic hepatitis C genotype 1 infection
California, Oct 2014: The US Food and Drug Administration (US FDA) has approved Gilead Sciences' Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, approved under the trade name Sovaldi in December 2013. Harvoni's efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naïve patients without cirrhosis who have baseline HCV viral load below 6 million IU/mL.
In today’s global environment, it doesn’t matter if you live in United States, Europe, Asia, India or Africa—everyone is at risk from unsafe drugs. Counterfeit drugs defraud consumers and deny patients therapies that can alleviate suffering and save lives. Unfortunately, in some cases, these drugs have caused great harm and fatalities.
But there are ways to minimize risk of getting a counterfeit medicine. The Partnership for Safe Medicines describes the various hidden poisons in form of counterfeit medication that consumers need to be aware of.
Frequently Asked Questions Q1. What is Pharmacovigilance?
Answer: Pharmacovigilance is the science and activities relating to the Detection, Assessment, Understanding and Prevention of adverse drug reactions or any other possible drug related problems. Generally speaking, pharmacovigilance is the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of drugs, biological products and traditional medicines with a view of identifying new information about hazards associated with medicines and preventing further harm to patients. The word pharmacovigilance has been derived from the Greek word pharmacon means ‘drug’ and the Latin word vigilare means ‘to keep awake or alert, to keep watch.’
Q2. What is the role of Pharmacovigilance Programme of India (PvPI)?
Answer: The mission of PvPI is to safeguard the health of the Indian population by ensuring that the benefit of use of medicine outweighs the risks associated with its use. The purpose of the PvPI is to collate data, analyze it and use the inferences to recommend informed regulatory interventions, besides communicating risks to healthcare professionals and the public and also detect and assess prescribing, dispensing and administration errors.
At present, Pharmacovigilance Programme of India is the main storehouse of suspected post-marketing adverse drug reactions in India. It ropes in medical colleges as Adverse drug reactions monitoring center (AMC). Once the Medical institute is enrolled as an AMC under PvPI, the AMC starts reporting ICSRs (Individual case safety reports) to NCC (National Coordinating center) via a VigiFlow software. These ICSRs are then assessed at NCC for quality of data and if found valid, they are further committed to the global drug monitoring center “Uppsala Monitoring Centre” in Sweden. PvPI aspires to expand the Pharmacovigilance programme to all hospitals (govt. & private) and centers of public health programs located across India, to develop and implement electronic reporting system (e-reporting) and to make ADR reporting mandatory for all healthcare professionals.
To read more visit at: http://www.ipc.gov.in/PvPI/pv_home.html